Published in Cancers (Basel) on August 10, 2011
DNA vaccination against oncoantigens: A promise. Oncoimmunology (2012) 0.85
Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. Front Oncol (2013) 0.81
Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice. Biomed Res Int (2014) 0.81
The Promise of Preventive Cancer Vaccines. Vaccines (Basel) (2015) 0.77
Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. Vaccines (Basel) (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Systemic spread is an early step in breast cancer. Cancer Cell (2008) 7.91
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood (2003) 3.47
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer (2004) 2.20
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Vaccines for tumour prevention. Nat Rev Cancer (2006) 1.87
Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today (1998) 1.86
Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther (2009) 1.69
2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66
What's wrong with our cancer models? Nat Rev Drug Discov (2005) 1.52
Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther (2007) 1.52
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res (2004) 1.49
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol (2004) 1.46
Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med (2006) 1.41
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res (2004) 1.38
Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine (2002) 1.34
Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol (2008) 1.30
In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta (1999) 1.24
A new generation of mouse models of cancer for translational research. Clin Cancer Res (2006) 1.22
Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol (2006) 1.21
Potentiation of an anthrax DNA vaccine with electroporation. Vaccine (2008) 1.21
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest (2003) 1.17
T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci U S A (1995) 1.15
Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res (2006) 1.13
Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol (2006) 1.12
Vaccination for treatment and prevention of cancer in animal models. Adv Immunol (2006) 1.11
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol (1996) 1.10
Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother (2003) 1.09
Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol (2005) 1.06
Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol (2003) 1.05
Cancer immunoprevention. Future Oncol (2005) 1.05
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res (2010) 1.05
Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res (2010) 1.05
Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res (2004) 1.04
Cost-effectiveness analysis of electrochemotherapy with the Cliniporatortrade mark vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag (2008) 1.04
Electrochemotherapy: a new treatment of solid tumors. J Exp Clin Cancer Res (2003) 1.04
Molecular pathological approaches to human tumor immunology. Pathol Int (2009) 1.04
Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol (2010) 1.04
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat (2011) 1.02
Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol (2007) 1.02
Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res (2008) 1.02
Electroporation for drug and gene delivery in the clinic: doctors go electric. Methods Mol Biol (2008) 1.01
ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol (2008) 1.00
Dendritic cells: a critical player in cancer therapy? J Immunother (2008) 0.99
Application of electroporation gene therapy: past, current, and future. Methods Mol Biol (2008) 0.97
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther (2008) 0.92
Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets (2011) 0.91
Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer (2007) 0.91
Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev (2009) 0.90
Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int J Cancer (2007) 0.90
Immunobiology of her-2/neu transgenic mice. Breast Dis (2004) 0.89
Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol (2010) 0.89
From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev (2001) 0.89
Effects of electrochemotherapy with bleomycin on normal liver tissue in a rat model. Eur J Cancer (2001) 0.82
Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks. J Virol (2011) 0.82
Viral vectors for cancer immunotherapy. Front Biosci (2006) 0.82
Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans? Drug News Perspect (2010) 0.81
DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther (2007) 0.81
Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. Curr Cancer Drug Targets (2008) 0.81
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res (2006) 1.92
Vaccines for tumour prevention. Nat Rev Cancer (2006) 1.87
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood (2011) 1.76
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood (2009) 1.65
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res (2009) 1.64
Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res (2010) 1.60
Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica (2006) 1.58
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood (2013) 1.57
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 1.52
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood (2007) 1.47
State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues? BMC Bioinformatics (2013) 1.45
A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. Cancer Prev Res (Phila) (2011) 1.43
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res (2004) 1.38
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood (2004) 1.37
State-of-the-art fusion-finder algorithms sensitivity and specificity. Biomed Res Int (2013) 1.35
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res (2004) 1.25
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A (2006) 1.22
Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res (2005) 1.18
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest (2003) 1.17
Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology (2013) 1.14
Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res (2006) 1.13
Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol (2006) 1.12
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest (2004) 1.10
Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia (2008) 1.07
Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res (2008) 1.06
p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. EMBO J (2007) 1.06
Cancer immunoprevention. Future Oncol (2005) 1.05
p130Cas is an essential transducer element in ErbB2 transformation. FASEB J (2010) 1.05
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res (2010) 1.05
Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res (2010) 1.05
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J (2004) 1.03
Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hematol (2007) 1.03
Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther (2008) 1.03
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood (2005) 1.01
Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma (2006) 1.01
ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol (2008) 1.00
The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB J (2013) 0.99
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol (2005) 0.97
The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians. Eur J Pharmacol (2008) 0.97
The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One (2011) 0.97
A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis (2012) 0.96
Transfection efficiency boost by designer multicomponent lipoplexes. Biochim Biophys Acta (2007) 0.95
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica (2010) 0.94
Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Mol Carcinog (2010) 0.94
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis (2007) 0.94
LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res (2003) 0.94
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol (2007) 0.92
Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem (2009) 0.92
Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One (2010) 0.92
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma (2012) 0.91
Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets (2011) 0.91
Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res (2005) 0.91
Restricted innervation of uterus and placenta during pregnancy: evidence for a role of the repelling signal Semaphorin 3A. Dev Dyn (2004) 0.91
Structural stability and increase in size rationalize the efficiency of lipoplexes in serum. Langmuir (2009) 0.90
DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Clin Cancer Res (2008) 0.90
Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine (2003) 0.90
miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. Am J Pathol (2013) 0.90
Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum Gene Ther (2008) 0.90
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. J Clin Oncol (2003) 0.89
Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol (2010) 0.89
In vitro antiproliferative effect of six Salvia species on human tumor cell lines. Phytother Res (2006) 0.89
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res (2014) 0.89
The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine (2005) 0.88
Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer (2005) 0.88
Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells. Carcinogenesis (2005) 0.88
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica (2010) 0.88
Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol (2010) 0.87
Role of consolidation/maintenance therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk (2013) 0.87
Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. Cancer Res (2007) 0.87
The impact of early life permethrin exposure on development of neurodegeneration in adulthood. Exp Gerontol (2011) 0.87
Medullospheres from DAOY, UW228 and ONS-76 cells: increased stem cell population and proteomic modifications. PLoS One (2013) 0.87
Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res (2007) 0.87
AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. Cancer Biother Radiopharm (2010) 0.86
p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells. Breast Cancer Res (2012) 0.86
Evaluation of antioxidative properties of Allium species growing wild in Italy. Phytother Res (2007) 0.86
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. BMC Genomics (2014) 0.86
Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res (2010) 0.85
Tumor vessel compression hinders perfusion of ultrasonographic contrast agents. Neoplasia (2005) 0.85
DNA vaccination against oncoantigens: A promise. Oncoimmunology (2012) 0.85
Factors determining the superior performance of lipid/DNA/protammine nanoparticles over lipoplexes. J Med Chem (2011) 0.84
Immunological inhibition of carcinogenesis. Cancer Immunol Immunother (2004) 0.84
Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol (2006) 0.84
Multi-level model for the investigation of oncoantigen-driven vaccination effect. BMC Bioinformatics (2013) 0.83
Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. Int J Cancer (2009) 0.83